A novel BLK-induced tumor model.

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• B-lymphoid tyrosine kinase (BLK) is a SRC family kinase involved in B-cell signaling.
• Ectopic BLK expression is implicated in various cancers, including T-cell malignancies, breast, kidney, and lung cancers.
• The precise role of BLK in lymphomagenesis and its oncogenic potential require further elucidation.

Purpose of the Study:

• To investigate the oncogenic potential of human BLK.
• To establish a BLK activity-dependent tumor model for in vivo studies.
• To evaluate the efficacy of SRC family kinase inhibitors in targeting BLK-induced tumors.

Main Methods:

• Engraftment of Ba/F3 cells expressing wild-type or constitutively active human BLK in mice.
• Tumor formation assessment in vivo.
• Inhibition of tumor growth using the SRC family kinase inhibitor dasatinib.

Main Results:

• Engrafted Ba/F3 cells expressing constitutively active human BLK formed tumors in mice.
• Ba/F3 cells expressing wild-type BLK or untransfected cells did not form tumors.
• Dasatinib treatment significantly inhibited the growth of BLK-induced tumors.

Conclusions:

• Human BLK functions as a proto-oncogene, capable of inducing tumor formation.
• A novel, BLK activity-dependent tumor model has been developed for studying lymphomagenesis.
• This model is suitable for screening novel BLK inhibitors in vivo.